Olema Pharmaceuticals, a clinical-stage biopharmaceutical company, has recently released its 10-K report, providing a detailed overview of its financial condition and operations. The company focuses on the discovery, development, and commercialization of therapies for women's cancers, with its lead product candidate being palazestrant, an estrogen receptor antagonist and selective ER degrader. Olema is also developing OP-3136, an orally-available small molecule that inhibits KAT6 for patients with ER+/HER2* metastatic breast cancer and other cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
In its 10-K report, Olema Pharmaceuticals stated that it had incurred significant operating losses since the commencement of its operations. The net losses were $162.5 million and $129.5 million for the years ended December 31, 2025, and 2024, respectively. The company anticipates incurring significant and increasing losses for the foreseeable future as it continues to advance its product candidates, make potential milestone payments to its licensors, and operate as a public company. As of December 31, 2025, Olema Pharmaceuticals had an accumulated deficit of $597.6 million.
Olema Pharmaceuticals has not generated any revenue from product sales and does not expect to generate any revenue from the sale of products for the foreseeable future. Its primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and general and administrative expenditures. The company expects to continue to incur net operating losses for at least the next several years and anticipates that its research and development expenses, general and administrative expenses, and capital expenditures will continue to increase.
The company stated that it will require substantial additional funding to develop its product candidates and support its continuing operations beyond its current operating plans. It expects to finance its operations through the sale of equity, debt financings, or other capital sources, which could include income from collaborations, strategic partnerships, or marketing, distribution, licensing, or other strategic arrangements with third parties, or from grants. Olema Pharmaceuticals may be unable to raise additional funds or enter into such agreements or arrangements on favorable terms, or at all, which could have a material adverse effect on its business, results of operations, or financial condition.
The 10-K report also highlighted the impact of global economic and business activities' uncertainty due to the geopolitical and macroeconomic environment, including economic and geopolitical uncertainty, market volatility, labor shortages, evolving trade and tariffs policies, supply chain disruptions, and related financial instability. Olema Pharmaceuticals continues to monitor the impact of these factors on its results of operations, financial condition, and cash flows. Today the company's shares have moved -7.02% to a price of $27.14. For more information, read the company's full 10-K submission here.
